Vivanta Industries Board Meeting Scheduled to Approve Q2 Financial Results and Review Qness Pharmaceuticals Agreement
Vivanta Industries Ltd has announced a meeting of its Board of Directors, which is scheduled to consider various operational, financial, and governance matters for the company. The Board meeting will be held on Friday, July 24, 2026, at 04:00 P.M. at the company's Registered office.The agenda items include the consideration and approval of the Unaudited Standalone and Consolidated Financial Results, along with the Limited Review Report for the quarter ended on June 30, 2026. Directors will also be asked to authorize signatories responsible for signing the Financial Statements for the financial year that concluded on March 31, 2026.
A significant item on the agenda is taking note of a Certain Business Collaboration agreement with Qness Pharmaceuticals, which operates as a proprietorship concern specializing in the manufacture, supply, branding, and marketing of pharmaceutical and allied products.
In addition to the key business partnership, the Board meeting will cover corporate governance aspects. This includes reviewing the Corporate Governance Report for the quarter ending June 30, 2026, and noting the E-Form DPT-3 Return of Deposits for the same period.
The meeting agenda also covers administrative matters. Directors are expected to take note of the issuance of Duplicate Share Certificate(s) in place of original certificates that were reported as lost or misplaced by shareholders.
Vivanta Industries Ltd has scheduled this Board meeting to transact these business points, including any other matter permitted by the Chair.
Stock Price Movement
As of 13:22, Vivanta Industries Ltd. shares are ticking up by 1.20% and trade at ₹1.69. The equity managed to move within an intraday range, reaching a high of ₹1.75 while dipping as low as ₹1.62.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.